AU2021258544A1 - Pharmaceutical composition comprising L-triiodothyronine (T3) for use in the treatment of tissue hypoxia and sepsis - Google Patents

Pharmaceutical composition comprising L-triiodothyronine (T3) for use in the treatment of tissue hypoxia and sepsis Download PDF

Info

Publication number
AU2021258544A1
AU2021258544A1 AU2021258544A AU2021258544A AU2021258544A1 AU 2021258544 A1 AU2021258544 A1 AU 2021258544A1 AU 2021258544 A AU2021258544 A AU 2021258544A AU 2021258544 A AU2021258544 A AU 2021258544A AU 2021258544 A1 AU2021258544 A1 AU 2021258544A1
Authority
AU
Australia
Prior art keywords
triiodothyronine
pharmaceutical composition
sepsis
hours
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021258544A
Other languages
English (en)
Inventor
Iordanis MOUROUZIS
Constantinos PANTOS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Uni Pharma Kleon Tsetis Pharmaceutical Laboratories SA
Original Assignee
Uni Pharma Kleon Tsetis Pharmaceutical Laboratories SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GR20200100200A external-priority patent/GR1010068B/el
Priority claimed from GR20200100695A external-priority patent/GR1010182B/el
Priority claimed from GR20210100216A external-priority patent/GR1010261B/el
Application filed by Uni Pharma Kleon Tsetis Pharmaceutical Laboratories SA filed Critical Uni Pharma Kleon Tsetis Pharmaceutical Laboratories SA
Publication of AU2021258544A1 publication Critical patent/AU2021258544A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2021258544A 2020-04-21 2021-04-15 Pharmaceutical composition comprising L-triiodothyronine (T3) for use in the treatment of tissue hypoxia and sepsis Pending AU2021258544A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GR20200100200 2020-04-21
GR20200100200A GR1010068B (el) 2020-04-21 2020-04-21 Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στη θεραπεια ασθενων σε κρισιμη κατασταση με λοιμωξη απο κορωνοϊο
GR20200100695 2020-11-23
GR20200100695A GR1010182B (el) 2020-11-23 2020-11-23 Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στην αντιμετωπιση της ιστικης υποξιας
GR20210100216 2021-03-29
GR20210100216A GR1010261B (el) 2021-03-29 2021-03-29 Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στην αντιμετωπιση της φλεγμονωδους αντιδρασης και της δυσλειτουργιας του καρδιαγγειακου συστηματος λογω σηψης
PCT/GR2021/000019 WO2021214497A1 (en) 2020-04-21 2021-04-15 Pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxemia and sepsis

Publications (1)

Publication Number Publication Date
AU2021258544A1 true AU2021258544A1 (en) 2022-10-27

Family

ID=76197481

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021258544A Pending AU2021258544A1 (en) 2020-04-21 2021-04-15 Pharmaceutical composition comprising L-triiodothyronine (T3) for use in the treatment of tissue hypoxia and sepsis

Country Status (13)

Country Link
US (1) US20230157982A1 (https=)
EP (1) EP4138810A1 (https=)
JP (1) JP2023538984A (https=)
KR (1) KR20230022839A (https=)
CN (1) CN115996710B (https=)
AU (1) AU2021258544A1 (https=)
BR (1) BR112022021250A2 (https=)
CA (1) CA3176106A1 (https=)
GE (2) GEP20247706B (https=)
IL (1) IL297398B1 (https=)
MX (1) MX2022013228A (https=)
WO (1) WO2021214497A1 (https=)
ZA (1) ZA202212502B (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1942995A (en) * 1994-03-15 1995-10-03 K.U. Leuven Research & Development New use of growth hormone
SI3908272T1 (sl) 2019-01-09 2023-07-31 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. L-trijodotironin (t3) za uporabo pri omejevanju mikrovaskularne obstrukcije

Also Published As

Publication number Publication date
JP2023538984A (ja) 2023-09-13
IL297398A (en) 2022-12-01
WO2021214497A1 (en) 2021-10-28
ZA202212502B (en) 2024-05-30
MX2022013228A (es) 2022-11-14
GEP20247706B (en) 2024-12-10
CA3176106A1 (en) 2021-10-28
IL297398B1 (en) 2026-01-01
BR112022021250A2 (pt) 2022-12-06
EP4138810A1 (en) 2023-03-01
GEAP202416094A (en) 2024-07-10
CN115996710A (zh) 2023-04-21
CN115996710B (zh) 2024-06-28
KR20230022839A (ko) 2023-02-16
US20230157982A1 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
Joannidis et al. Prevention of acute kidney injury and protection of renal function in the intensive care unit: expert opinion of the working group for nephrology, ESICM
Brochard et al. An official ATS/ERS/ESICM/SCCM/SRLF statement: prevention and management of acute renal failure in the ICU patient: an international consensus conference in intensive care medicine
Boldt et al. Influence of volume therapy with a modern hydroxyethylstarch preparation on kidney function in cardiac surgery patients with compromised renal function: a comparison with human albumin
Heather et al. Isoproterenol induces in vivo functional and metabolic abnormalities; similar to those found in the infarcted rat heart
US5998386A (en) Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue
Lin et al. CB1 cannabinoid receptor antagonist attenuates left ventricular hypertrophy and Akt-mediated cardiac fibrosis in experimental uremia
US11213514B2 (en) Alpha-1-adrenergic receptor agonist therapy
Yamaura et al. Effect of low-dose milrinone on gastric intramucosal pH and systemic inflammation after hypothermic cardiopulmonary bypass
Bersten et al. Respiratory mechanics and surfactant in the acute respiratory distress syndrome
US20230157982A1 (en) Pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxia and sepsis
Boldt et al. RETRACTED: Volume Replacement With a Balanced Hydroxyethyl Starch (HES) Preparation in Cardiac Surgery Patients
Pachtinger et al. Assessment and treatment of hypovolemic states
Morgan et al. Acid-base effects of a bicarbonate-balanced priming fluid during cardiopulmonary bypass: comparison with Plasma-Lyte 148. A randomised single-blinded study
Merritt Metabolism and liver transplantation: review of perioperative issues
Ishihara Kidney function after the intraoperative use of 6% tetrastarches (HES 130/0.4 and 0.42)
EA048898B1 (ru) Фармацевтическая композиция, содержащая l-трийодтиронин (т3), для применения при лечении тканевой гипоксии и сепсиса
HK40088108A (zh) 用於治疗组织缺氧和脓毒症的包含l-三碘甲腺原氨酸(t3)的药物组合物
HK40088108B (zh) 用於治疗组织缺氧和脓毒症的包含l-三碘甲腺原氨酸(t3)的药物组合物
Kuiper et al. Production of endothelin-1 and reduced blood flow in the rat kidney during lung-injurious mechanical ventilation
GR1010261B (el) Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στην αντιμετωπιση της φλεγμονωδους αντιδρασης και της δυσλειτουργιας του καρδιαγγειακου συστηματος λογω σηψης
WO2007129618A1 (ja) 好中球の活性化および遊走因子の抑制剤およびその利用
GR1010182B (el) Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στην αντιμετωπιση της ιστικης υποξιας
Perin et al. Low hematocrit impairs gastric mucosal CO2 removal during experimental severe normovolemic hemodilution
JP2003527420A (ja) 鬱血性心不全の治療方法
RU2696580C1 (ru) Способ профилактики нарушений функций почек ингибитором аргиназы II в эксперименте

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ PHARMACEUTICAL COMPOSITION COMPRISING L-TRIIODOTHYRONINE (T3) FOR USE IN THE TREATMENT OF TISSUE HYPOXIA AND SEPSIS